Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.48 EUR 0.09% Market Closed
Market Cap: 18.9B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Fresenius SE & Co KGaA
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fresenius SE & Co KGaA
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Fresenius SE & Co KGaA
XETRA:FRE
Non-Reccuring Items
-€45m
CAGR 3-Years
-36%
CAGR 5-Years
-86%
CAGR 10-Years
N/A
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Non-Reccuring Items
€1.7m
CAGR 3-Years
N/A
CAGR 5-Years
37%
CAGR 10-Years
11%
Vita 34 AG
XETRA:V3V
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Non-Reccuring Items
-HK$382k
CAGR 3-Years
N/A
CAGR 5-Years
49%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Non-Reccuring Items
-€45.6m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Non-Reccuring Items
€1.7m
CAGR 3-Years
N/A
CAGR 5-Years
37%
CAGR 10-Years
11%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.9B EUR
Industry
Health Care

Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income. Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.

FRE Intrinsic Value
73.78 EUR
Undervaluation 55%
Intrinsic Value
Price

See Also

What is Fresenius SE & Co KGaA's Non-Reccuring Items?
Non-Reccuring Items
-45m EUR

Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Non-Reccuring Items amounts to -45m EUR.

What is Fresenius SE & Co KGaA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
-86%

Over the last year, the Non-Reccuring Items growth was -18%. The average annual Non-Reccuring Items growth rates for Fresenius SE & Co KGaA have been -36% over the past three years , -86% over the past five years .

Back to Top